GREEN TECHNOLOGY,CREATE BETTER LIFE GREEN TECHNOLOGY,CREATE BETTER LIFE

GREEN TECHNOLOGY,CREATE BETTER LIFE

查看详情+
GREEN TECHNOLOGY,CREATE BETTER LIFE GREEN TECHNOLOGY,CREATE BETTER LIFE

GREEN TECHNOLOGY,CREATE BETTER LIFE

查看详情+
GREEN TECHNOLOGY,CREATE BETTER LIFE GREEN TECHNOLOGY,CREATE BETTER LIFE

GREEN TECHNOLOGY,CREATE BETTER LIFE

查看详情+

ABOUT US

SyncoZymes (Shanghai) Co., Ltd. is founded in 2007 and located in southern district of Shanghai Pudong Zhangjiang High-tech Park, the International Medical Park. SyncoZymes (Shanghai) is a subsidiary company of SyncoZymes (Zhejiang) Co., Ltd. SyncoZymes is committed to the research and development of cutting-edge technologies and products in the field of green pharmaceuticals, leading the development of the chemical pharmaceutical industry with green biotechnology, and providing high-quality products and services to the customers of pharmaceutical and healthy industry.

  • Enzymes
    SyncoZymes has a large enzyme library with 40 series and more than 10,000 enzymes, which can be applied to various types of chemical transformation reactions. Each type of enzyme can be made into enzyme plate for high-throughput screening. The company provides enzyme plate screening services, as well as the development of enzymes for biotransformation, the design and optimization of biotransformation processes, and the transfer of strains.
    More +
  • Co-enzymes
    SyncoZymes supplies co-enzyme of NAD series products, including NMN, NAD, NADP, NADH, NADPH, with an annual output of 100 tons, is one of the main suppliers of NAD-family coenzyme products in the world.
    More +
  • Functional Food Raw Materials
    SyncoZymes uses biocatalysis technology to develop green natural functional food raw materials, and produces them in strict accordance with the pharmaceutical standard system. It continuously explores the effects and mechanisms of natural ingredients on human health, realizes the green manufacturing of natural ingredients and provides scientific, safe and effective health for human beings.
    More +
  • Pharmaceutical Intermediates
    SyncoZymes has a strong biotechnology platform, chemical technology platform and GMP production system, focusing on the development and application of biological enzymes, focusing on the research and development and production of pharmaceutical intermediates.
    More +
  • CRO/CDMO Services
    SyncoZymes has a strong biotechnology platform, chemical technology platform, testing and quality research platform and GMP production system, focusing on the development and application research of biological enzymes, focusing on the research and development and application of green biotechnology pharmaceutical intermediates, APIs, functional food raw materials. At the same time, She provides high-end CRO, CDMO services, testing and quality research services.
    More +
  • Testing and Quality Research Services
    SyncoZymes undertakes the management and operation of the R&D public service platform in Shanghai International Medical Park, and can provide testing and quality research services for small molecule drug research and development. SyncoZymes equipped with NMR, LCMS, GCMS, HPLC, GC, protein purification, crystal form detection, preparative chromatography and other instrument.
    More +
Products and Services
SyncoZymes (Shanghai) Co., Ltd., has a strong biotechnology platform, chemical technology platform, testing and quality research platform and GMP production platform. SyncoZymes focuses on the developing and applicating of biological enzymes and biocatalysis technologies, as well as synthetic biology technologies. SyncoZymes' main business is the research, development, production and sales of enzymes, co-enzymes, pharmaceutical intermediates, and functional food raw materials, and provides high-end CRO, CDMO services, testing and quality research services for customers.
Learn More

R & D system

25

2022-07

After strict review by the professional committee of the US FDA (US Food and Drug Administration) authoritative organization, on May 17, 2022, SyncoZymes (Shanghai) Co., Ltd. officially received the FDA's confirmation letter (AKL): NMN raw material successfully passed NDI (New Dietary Ingredient) approval.

15

2024-01

Recently, Australian researchers published scientific research results in the Journal of Gerontology: Series A: NMN can reduce the aging of human bone cells and promote bone healing in osteoporotic mice. "The findings demonstrate NMN as an effective and feasible therapeutic candidate to prevent osteoporosis and enhance bone healing in older adults with osteoporosis," the authors said.

19

2023-05

For patients with chronic hepatitis B, the high level exposure of hepatitis B virus-specific immune cells (CD8 T cells) to pathogens such as hepatitis B virus has caused DNA damage and dysfunction of CD8 T cells. Identifying the cellular process behind CD8 T cell damage is helpful to develop the treatment of chronic hepatitis B.. Recent studies have shown that NAD+ depletion is the basis of CD8 T cell depletion.

07

2023-01

As we grow older, we are more likely to suffer from cardiovascular complications-retinal dysfunction. The retina is the part of the eye responsible for receiving light signals, which can easily lead to retinal dysfunction due to cardiovascular diseases (such as carotid artery occlusion).

16

2022-12

Since December 2022, due to the reduction of virus toxicity, China has started to optimize epidemic prevention and control, precise prevention and control, and scientific prevention and control, including measures such as lifting temporary control areas and not checking nucleic acid certificates when going in and out of major places, which shows that the dynamic optimization of epidemic prevention and control has entered a new stage.
×

Search

Search
×